Eyeing untapped niche, EpicentRx makes case for cancer toxicity prevention drug

by EpicentRx | Jan 20, 2023 | Media

EpicentRx Announces Presentation for Phase 2 Randomized, Active-controlled, Multicenter Trial to Assess the Safety and Efficacy of RRx-001 vs. regorafenib in Third/Fourth Line Colorectal Cancer at the 2023 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium

by EpicentRx | Jan 20, 2023 | 2023, Press Releases

Torrey Pines, Calif., January 20, 2023 – EpicentRx, Inc, a leading-edge, clinical-stage biopharmaceutical company that uses groundbreaking science to treat cancer and inflammatory-driven diseases, today announced data from a Phase 2 randomized clinical trial of...

EpicentRx Publishes Phase 2 Results for RRx-001 as an Anti-Mucositis Agent in Patients Receiving Radiation for Head and Neck Cancers

by EpicentRx | Jan 19, 2023 | 2023, Press Releases

Results from PREVLAR trial Demonstrate RRx-001 protects against severe oral mucositis or blistering from radiation in first line head and neck cancer Study published in International Journal of Radiation Oncology, Biology and Physics, also known as The Red Journal...

PREVLAR: Phase 2a randomized trial to assess the safety and efficacy of RRx-001 in the attenuation of oral mucositis in patients receiving head and neck chemoradiotherapy

by EpicentRx | Jan 13, 2023 | Media

RRx-001 Plus Irinotecan Improves Efficacy vs Regorafenib in Colorectal Cancer

by EpicentRx | Jan 13, 2023 | Media